Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- Journal
- Oxford University Research Archive (ORA) (University of Oxford)
In The Last Decade
doi.org/w13685335 →Countries where authors are citing Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
This map shows the geographic impact of Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial more than expected).
Fields of papers citing Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
This network shows the impact of Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
About Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
This paper, published in 2020, received 817 indexed citations . Written by Angela M. Minassian, Amy Flaxman, Pedro M. Folegatti, Parvinder K. Aley, Katherine R. W. Emary, Mimi M. Hou, Carina C. D. Joe, Elizabeth J. Kelly, Alison M. Lawrie and Natalie G. Marchevsky covering the research area of Genetics, Cardiology and Cardiovascular Medicine and Infectious Diseases. It is primarily cited by scholars working on Infectious Diseases (704 citations), Health (277 citations) and Immunology (102 citations). Published in Oxford University Research Archive (ORA) (University of Oxford).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w13685335.